Henry Holets, MD
Family Medicine · Monongahela, PANPI 1083638043
Payments from drug & device makers
Across 581 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Novo Nordisk$1K
- AbbVie$797
- Johnson & Johnson$787
- Lilly USA, LLC$613
- plus $4K from 31 others
What the payments were for
- Food & beverage$10,874100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 95 | $1,990 |
| AstraZeneca | 63 | $1,221 |
| Novo Nordisk | 64 | $1,110 |
| AbbVie(2 entities) | 58 | $797 |
| Johnson & Johnson | 31 | $787 |
| Lilly USA, LLC | 39 | $613 |
| Amgen | 36 | $599 |
| Bayer | 31 | $501 |
| Pfizer | 25 | $489 |
| Boehringer Ingelheim | 29 | $460 |
| E.r. Squibb & Sons, L.L.C. | 15 | $343 |
| Novartis | 14 | $284 |
| Esperion Therapeutics, Inc. | 7 | $259 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $194 |
| Abbott | 7 | $185 |
| Amarin Pharma, Inc. | 12 | $181 |
| Biohaven Pharmaceuticals, Inc. | 3 | $145 |
| Merck | 9 | $135 |
| Advanced Respiratory, Inc | 4 | $78 |
| Exact Sciences | 4 | $74 |
| Phathom Pharmaceuticals, Inc. | 4 | $64 |
| Eisai Inc. | 5 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Corcept Therapeutics | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Boston Scientific | 1 | $21 |
| UCB, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Smith+Nephew | 1 | $13 |
| Seqirus USA Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$231
- TRELEGY ELLIPTA$125
- NURTEC ODT$125
- AREXVY$125
- BREZTRI$101
How this compares
$10,880 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 155 | $105,539 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 130 | $101,162 |
| JardianceEmpagliflozin | 75 | $61,908 |
| RybelsusSemaglutide | 47 | $59,785 |
| XareltoRivaroxaban | 71 | $51,526 |
| FarxigaDapagliflozin Propanediol | 47 | $46,301 |
| MounjaroTirzepatide | 33 | $38,425 |
| EntrestoSacubitril/Valsartan | 43 | $28,300 |
| OzempicSemaglutide | 26 | $26,108 |
| PentasaMesalamine | 12 | $18,284 |
| TradjentaLinagliptin | 17 | $16,777 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $15,351 |
| JanuviaSitagliptin Phosphate | 19 | $15,325 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $8,238 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $7,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,990 | $122,733179 claims |
| PfizerEliquis | $489 | $105,539155 claims |
| Novo NordiskRybelsus, Ozempic | $1,110 | $85,89373 claims |
| Boehringer IngelheimJardiance, Tradjenta | $460 | $78,68692 claims |
| Johnson & JohnsonXarelto | $787 | $51,52671 claims |
| AstraZenecaFarxiga | $1,221 | $46,30147 claims |
| Lilly USA, LLCMounjaro | $613 | $38,42533 claims |
| NovartisEntresto | $284 | $28,30043 claims |
| MerckJanuvia, Janumet | $135 | $22,53031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Monongahela
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.